Cancer Resources from OncoLink | Treatment, Research, Coping, Clinical Trials, Prevention

RELATED TOPICS

Become a Fan

FEATURES

Nurses Notes

OncoPilot

OncoTips

Abramson
Cancer Center

Continuing
Education

Newsletter

Cancer Clinical Trials Matching

ONCOLINK ART GALLERY

Conferences

Conferences > OncoLink Scientific Meetings Coverage > OncoLink at ISH 2007 > Highlights from ISH 2007

Coverage from the XXXI World Congress of the International Society of Hematology (ISH) in Punta del Este, Uruguay from March 20-24, 2007.

Myeloma Multiple

Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL)

Correlation Between the Uptake of Tc-99m-sesta MIBI and Prognostic Factors in Patients with Multiple Myeloma

Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area

Expression of CD56 As A Prognostic Factor in Multiple Myeloma

Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance (MGUS): Experience of One Institution

Leukemia

Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL)

Acute Lymphoblastic Leukemia (ALL): Detection of Prognostically Significance Fusion-Genes By Multiplex-Polymerase Chain Reaction (M-PCR)

Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years

Acute Promyelocytic Leukemia (APL): Genetic Characterization of 78 Argentinian And Uruguayan Patients

Acute Promyelocytic Leukemia, Twelve Years Experience at the University Hospital,San Juan, Puerto Rico

Allogeneic Stem Cell Transplant with TBI/CY/Cytarabine Conditioning for Childhood Philadelphia-Positive ALL

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib and Prognosis

FLT3 gene internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML)

Monitoring Response to Imatinib By Fluorescence In Situ Hibridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) In Chronic Myeloid Leukemia (CML) Patients (PTS) In Chronic Phase (CP): Experience of Argentina and Uruguay

Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia (ALL).

Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia

Prognostic Value of Different Profiles of the Early Response to Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Results in the Treatment With Chemotherapy in Acute Myeloid Leukemias. Experience of 20 Years

siRNA-Inhibition OF E2A-PBX1 in Pre-B Leukemia Cells

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL): A Single Centre Experience

Lymphomas

Analysis of 511 Lymphoma Cases in Uruguay

Cutaneous Lymphomas: Experience of a single institution in Lima-Perú

Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report

Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL)

A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group

Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study

Transplant

Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease

In Vitro CD4+ T Cells Expansion: Induction of Regulatory T Cells with Sirolimus and CD3/CD28 Dynabeads